clinical trial · NCT07662096
A First-In-Human Study of ARO-033 in Adult Participants
Healthy ParticipantsARO-033Placebo
brief summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs).
started
Jun 25, 2026
primary completion
Jul 18, 2027
completion
Jul 18, 2027
last updated
Jul 22, 2026
official title
A First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol